Diclofenac sodium and Injection site discoloration - a phase IV clinical study of FDA data

Summary:

Injection site discoloration is reported as a side effect among people who take Diclofenac sodium (diclofenac sodium), especially for people who are female, 50-59 old, also take Humira, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Injection site discoloration when taking Diclofenac sodium. It is created by eHealthMe based on reports of 41,731 people who have side effects when taking Diclofenac sodium from the FDA, and is updated regularly.

What is Diclofenac sodium?

Diclofenac sodium has active ingredients of diclofenac sodium. It is often used in arthritis. eHealthMe is studying from 43,018 Diclofenac sodium users. Check the latest studies of Diclofenac sodium.

What is Injection site discoloration?

Injection site discoloration is found to be associated with 501 drugs and 597 conditions by eHealthMe. Check the latest studies of Injection site discoloration.

On Jul, 12, 2026

41,731 people reported to have side effects when taking Diclofenac sodium.
Among them, 23 people (0.06%) have Injection site discoloration.

Could Diclofenac sodium cause Injection site discoloration?

Among these 23 people:

What is the gender of people who have Injection site discoloration when taking Diclofenac sodium? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Injection site discoloration when taking Diclofenac sodium? *

What are other drugs people take besides Diclofenac sodium? *

What are other side effects people have besides Injection site discoloration? *

Injection Site Pain: 13 people, 56.52%
Embolia Cutis Medicamentosa (livedoid dermatitis occurs immediately after an intramuscular injection): 9 people, 39.13%
Injection Site Erythema (redness at injection site): 7 people, 30.43%
Injection Site Induration: 5 people, 21.74%
Scar: 4 people, 17.39%
Injection Site Reaction: 4 people, 17.39%
Injection Site Bruising: 3 people, 13.04%
Injection Site Necrosis (death of body tissue at injection site): 3 people, 13.04%
Injection Site Ulcer: 3 people, 13.04%
Fatigue (feeling of tiredness): 3 people, 13.04%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 21.74%
Joint Pain: 3 people, 13.04%
High Blood Pressure: 3 people, 13.04%
Ligament Sprain (ligament stretched): 2 people, 8.70%
Escherichia Infection (bacterial infection by escherichia coli): 2 people, 8.70%
Gastritis (inflammation of stomach): 2 people, 8.70%
Ankylosing Spondylitis (type of arthritis affecting the spine): 2 people, 8.70%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.35%
Osteoporosis (bones weak and more likely to break): 1 person, 4.35%
Swelling: 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Diclofenac sodium and have Injection site discoloration?

- Check whether Injection site discoloration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Diclofenac sodium:

Diclofenac sodium (43,018 reports)

Browse all side effects of Diclofenac sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site discoloration:

Injection site discoloration (501 drugs)

Browse all the conditions that are associated with Injection site discoloration:

Injection site discoloration (597 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on diclofenac sodium (the active ingredients of Diclofenac sodium) and Diclofenac sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.